title: [Pulmonary hypertension due to chronic lung disease. Recommendations of the Cologne Consensus Conference 2010].
abstract: The 2009 European Guidelines on Pulmonary Hypertension did not cover only pulmonary arterial hypertension (PAH) but also some aspects of pulmonary hypertension (PH) in chronic lung disease. The European Guidelines point out that the drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors) have not been sufficiently investigated in other forms of PH. Therefore, the European Guidelines do not recommend the use of these drugs in patients with chronic lung disease and PH. This recommendation, however, is not always in agreement with medical ethics as physicians feel sometimes inclined to treat other form of pulmonary hypertension which may affect quality of life and survival of these patients in a similar manner. In June 2010, a group of German experts met in Cologne, Germany, to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. The conference was sponsored by the German Society of Cardiology, the German Society of Respiratory Medicine and the German Society of Pediatric Cardiology. One of the working groups was dedicated to the diagnosis and treatment of PH in patients with chronic lung disease. The recommendations of this working group are summarized in the present paper.
authors.affiliation: Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover. hoeper.marius@mh-hannover.de
authors.forename: M M
authors.initials: MM
authors.lastname: Hoeper
authors.forename: S
authors.initials: S
authors.lastname: Andreas
authors.forename: A
authors.initials: A
authors.lastname: Bastian
authors.forename: M
authors.initials: M
authors.lastname: Claussen
authors.forename: H A
authors.initials: HA
authors.lastname: Ghofrani
authors.forename: M
authors.initials: M
authors.lastname: Gorenflo
authors.forename: C
authors.initials: C
authors.lastname: Grohé
authors.forename: A
authors.initials: A
authors.lastname: Günther
authors.forename: M
authors.initials: M
authors.lastname: Halank
authors.forename: P
authors.initials: P
authors.lastname: Hammerl
authors.forename: M
authors.initials: M
authors.lastname: Held
authors.forename: S
authors.initials: S
authors.lastname: Krüger
authors.forename: T J
authors.initials: TJ
authors.lastname: Lange
authors.forename: F
authors.initials: F
authors.lastname: Reichenberger
authors.forename: A
authors.initials: A
authors.lastname: Sablotzki
authors.forename: G
authors.initials: G
authors.lastname: Staehler
authors.forename: W
authors.initials: W
authors.lastname: Stark
authors.forename: H
authors.initials: H
authors.lastname: Wirtz
authors.forename: C
authors.initials: C
authors.lastname: Witt
authors.forename: J
authors.initials: J
authors.lastname: Behr
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005060:Europe; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology*; D055370:Lung Injury / Q000150:complications* / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D015272:Pulmonary Medicine / Q000592:standards*
chemical_list: D000959:Antihypertensive Agents